Hostname: page-component-7b7567c8c-z4zkx Total loading time: 0 Render date: 2026-11-18T02:09:30.755Z Has data issue: false hasContentIssue false

Could changes in national tuberculosis vaccination policies be ill-informed ?

Published online by Cambridge University Press:  06 June 2012

D.J. Gerberry*
Affiliation:
Department of Mathematics and Computer Science, Xavier University, 3800 Victory Parkway, Cincinnati, Ohio 45207, USA
F.A. Milner
Affiliation:
School of Mathematical and Statistical Sciences, Arizona State University, P.O. Box 871804, Tempe, Arizona 85287, USA
*
⋆ Corresponding author. E-mail: david.gerberry@xavier.edu

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

National policies regarding the BCG vaccine for tuberculosis vary greatly throughout the international community and several countries are currently considering discontinuing universal vaccination. Detractors of BCG point to its uncertain effectiveness and its interference with the detection and treatment of latent tuberculosis infection (LTBI).

In order to quantify the trade-off between vaccination and treatment of LTBI, a mathematical model was designed and calibrated to data from Brazil, Ghana, Germany, India, Mexico, Romania, the United Kingdom and the United States. Country-specific thresholds for when LTBI treatment outperforms mass vaccination were found and the consequences of policy changes were estimated.

Our results suggest that vaccination outperforms LTBI treatment in all settings but with greatly reduced efficiency in low incidence countries. While national policy statements emphasize BCG’s interference with LTBI detection, we find that reinfection should be more determinant of a country’s proper policy choice.

Information

Type
Research Article
Copyright
© EDP Sciences, 2012